Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)

Market Cap	5.41T
Revenue (ttm)	220.74B
Net Income (ttm)	-11.40B
Shares Out	23.26M
EPS (ttm)	-490.31
PE Ratio	n/a
Forward PE	n/a
Dividend	200.00 (0.09%)
Ex-Dividend Date	n/a

Volume	110,114
Average Volume	168,651
Open	230,500
Previous Close	232,500
Day's Range	227,500 - 235,500
52-Week Range	127,600 - 268,500
Beta	1.75
RSI	54.40
Earnings Date	Mar 18, 2026

About Sam Chun Dang Pharm.

Sam Chun Dang Pharm. Co., Ltd engages in the manufacturing and sale of pharmaceutical products in South Korea. It provides ethical and over the counter products in various therapeutic areas comprising ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company is also involved in exporting activities. Sam Chun Dang Pharm. Co., Ltd was founded in 1943 and is headquartered in Seoul, S...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1943
• Employees: 422
• Stock Exchange: KOSDAQ
• Ticker Symbol: 000250

Financial Performance

In 2024, Sam Chun Dang Pharm.'s revenue was 210.92 billion, an increase of 9.47% compared to the previous year's 192.67 billion. Losses were -10.92 billion, 5.14% more than in 2023.